1 / 8

Acromegaly Treatment Market to Reach $2.10 Billion by 2025 | Grand View Research

Acromegaly Treatment Market Size, Share & Trends Analysis Report By Product (Somatostatin analogs, GHRA), By End Use (Hospitals & Clinics), By Region, And Segment Forecasts, 2019 - 2025

Marsh
Download Presentation

Acromegaly Treatment Market to Reach $2.10 Billion by 2025 | Grand View Research

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Acromegaly Treatment Market Analysis, Size, Growth, Share & Forecast to 2025 | Grand View Research Inc. “Acromegaly Treatment Market Size Worth $2.10 Billion By 2025” The global Acromegaly Treatment Market size is expected to reach USD 2.10 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to register a CAGR of 7.5% over the forecast period. Increasing incidence of the acromegaly disease is expected to drive the growth. For instance, the disease prevalence increased fourfold in 2015 from its previous year 2014, according to a report by the Endocrine Society. Moreover, growing investment in clinical trials by various pharmaceutical companies to develop new molecules is another factor propelling the market growth. Furthermore, strong pipeline of drugs is anticipated to create growth opportunities in the forthcoming years. For instance, Mycapssa by Chiasma Inc. received approval in Europe in 2016. In 2018, Antisense Therapeutics launched their new formulation ALT1103 in U.S. ISIS 766720 by Ionis Pharmaceuticals Inc., a growth hormone receptor antagonist is currently under phase II clinical trial and is expected to be finished by December 2019. The strong pipeline of drugs for somatostatin analogs is expected to propel growth of the acromegaly treatment market in near future. For instance, in 2018 around 30 clinical trials were being conducted in North America and many are waiting for the U.S. Food and Drug Administration (FDA) approval. Further key findings from the report suggest: Somatostatin analogs segment is expected to emerge as the largest product segment in terms of revenue share in the forthcoming years, owing to easy availability and cost-effective treatment procedure of the product • Follow Us:

  2. Hospital and clinics end use segment accounted for the largest market share as all the surgical procedures are performed in these facilities. Easy availability of surgeons Is anticipated to further drive the segment • North America held the dominant market share in 2018, due to favorable government insurance policies and increased investment in R&D by the pharmaceutical companies. For instance, In May 2018, U.S. Congress approved the Right to Try bill, wherein patients can try unproven medical therapeutics in case of serious illness including orphan diseases like acromegaly • Asia Pacific acromegaly treatment market is anticipated to witness lucrative growth in near future due to rising healthcare expenditure and R&D initiatives by pharmaceutical companies • Some of the key players are Novartis AG; Ipsen Pharma; Pfizer Inc.; and Chiasma Inc. • Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/acromegaly-treatment-market Grand View Research has segmented the global acromegaly treatment market on the basis of product, end use and region: Acromegaly Treatment Product Outlook (Revenue, USD Million, 2014 - 2025) Somatostatin Analogs • GHRA • Others • Acromegaly Treatment End Use Outlook (Revenue, USD Million, 2014 - 2025) Hospitals & Clinics • Others • Acromegaly Treatment Regional Outlook (Revenue, USD Million, 2014 - 2025) North America • oU.S. oCanada Europe • oU.K. oGermany oFrance Follow Us:

  3. oItaly oSpain Asia Pacific • oChina oIndia oJapan Latin America • oBrazil oMexico Middle East & Africa • oSouth Africa Table of Content Chapter 1 Report Scope 1.1 Segment Market Scope 1.2 Regional Scope 1.3 Estimates & Forecast Timeline Chapter 2 Research Methodology 2.1 Model Details 2.1.1 Regression and variable analysis 2.2 Information Procurement 2.3 List Of Primary Sources 2.3.1 Purchased database: 2.3.2 GVR’s internal database 2.4 Primary Interview Breakup 2.4.1 Data for primary interviews, by sources 2.4.2 Data for primary interviews, by region 2.5 List Of Secondary Sources Chapter 3 Report Objectives 3.1 Objectives Chapter 4 Executive Summary Follow Us:

  4. 4.1 Market Summary Chapter 5 Market Definitions 5.1 Definitions Chapter 6 Acromegaly Treatment market: Industry Outlook 6.1 Market Variable Analysis 6.2 Market Driver Analysis 6.2.1 Increasing prevalence of acromegaly 6.2.3 Ongoing clinical trials 6.3 Market Restraints Analysis 6.3.1 High treatment cost 6.3.2 Lack of awareness among people 6.4 Business Environment Analysis Tools 6.4.1 Acromegaly Treatment market - SWOT Analysis, By Factor (Political & Legal, Economic And Technological) 6.4.2 Porter’s Five Forces Analysis Chapter 7 Regulatory & Political Forces 7.1 Regulatory Landscape 7.1.1 List of regulations, by country 7.1.2 North America 7.1.4 Europe 7.1.5 Asia Pacific 7.1.7 Latin America 7.1.9 MEA 7.2 Political Landscape, Current & Future Scenario Chapter 8 Competitive & Vendor Landscape 8.1 Market Participation Categorization 8.1.1 Market leader 8.1.2 Innovators 8.2 Strategic Initiatives & Outcome Analysis 8.3 List of Key Companies, By Product 8.4 Company Market Share Analysis 8.4.1 Acromegaly treatment market company market share analysis, 2017 Chapter 9 Acromegaly Treatment Market: Product Analysis 9.1 Product Business Analysis Follow Us:

  5. 9.2 Somatostatin analogs (SSA) 9.2.1 Somatostatin analogs (SSA) estimates and forecasts, 2014 - 2025 (USD Million) 9.3 GHRA 9.3.1 GHRA market estimates and forecasts, 2014 - 2025 (USD Million) 9.4 Others 9.4.1 others market estimates and forecasts, 2014 - 2025 (USD Million) Chapter 10 Acromegaly Treatment market: End Use Analysis 10.1 End Use Business Analysis 10.2 Hospitals 10.2.1 hospitals estimates and forecasts, 2014 - 2025 (USD Million) 10.3 Clinics 10.3.1 clinics market estimates and forecasts, 2014 - 2025 (USD Million) 10.4 Others 10.4.1 others market estimates and forecasts, 2014 - 2025 (USD Million) Chapter 11 Acromegaly Treatment Market: Regional Analysis 11.1 North America 11.1.1 North America Acromegaly treatment market estimates and forecasts, 2014 - 2025 (USD Million) 11.1.2 U.S. 11.1.2.1 U.S. Acromegaly treatment market estimates and forecasts, 2014 - 2025 (USD Million) 11.1.3 Canada 11.1.3.1 Canada Acromegaly treatment market estimates and forecasts, 2014 - 2025 (USD Million) 11.2 Europe 11.2.1 Europe Acromegaly treatment market estimates and forecasts, 2014 - 2025 (USD Million) 11.2.2 Germany 11.2.2.1 Germany Acromegaly treatment market estimates and forecasts, 2014 - 2025 (USD Million) 11.2.3 U.K. 11.2.3.1 U.K. Acromegaly treatment market estimates and forecasts, 2014 - 2025 (USD Million) 11.2.4 France 11.2.4.1 France Acromegaly treatment market estimates and forecasts, 2014 - 2025 (USD Follow Us:

  6. Million) 11.2.5 Italy 11.2.5.1 Italy Acromegaly treatment market estimates and forecasts, 2014 - 2025 (USD Million) 11.2.6 Spain 11.2.6.1 Spain Acromegaly treatment market estimates and forecasts, 2014 - 2025 (USD Million) 11.3 Asia Pacific 11.3.1 Asia Pacific Acromegaly treatment market estimates and forecasts, 2014 - 2025 (USD Million) 11.3.2 China 11.3.2.1 China Acromegaly treatment market estimates and forecasts, 2014 - 2025 (USD Million) 11.3.3 India 11.3.3.1 India Acromegaly treatment market estimates and forecasts, 2014 - 2025 (USD Million) 11.3.4 Japan 11.3.4.1 Japan Acromegaly treatment market estimates and forecasts, 2014 - 2025 (USD Million) 11.4 Latin America 11.4.1 Latin America Acromegaly treatment market estimates and forecasts, 2014 - 2025 (USD Million) 11.4.2 Mexico 11.4.2.1 Mexico Acromegaly treatment market estimates and forecasts, 2014 - 2025 (USD Million) 11.4.3 Brazil 11.4.3.1 Brazil Acromegaly treatment market estimates and forecasts, 2014 - 2025 (USD Million) 11.5 MEA 11.5.1 MEA Acromegaly treatment market estimates and forecasts, 2014 - 2025 (USD Million) 11.5.2 South Africa 11.5.2.1 South Africa acromegaly treatment market estimates and forecasts, 2014 - 2025 (USD Million) Chapter 12 Company Profiles Follow Us:

  7. 12.1 Key Company Profiles 12.1.1 Novartis AG 12.1.1.1 Company overview 12.1.1.2 Financial performance 12.1.1.3 Product benchmarking 12.1.1.4 Strategic initiatives 12.1.2 Ipsen Pharma 12.1.2.1 Company overview 12.1.2.2 Financial performance 12.1.2.3 Product benchmarking 12.1.2.4 Strategic initiatives 12.1.3 SUN PHARMACEUTICAL INDUSTRIES LTD. 12.1.3.1 Company overview 12.1.3.2 Product benchmarking 12.1.3.3 Strategic initiatives 12.1.4 Chiasma, Inc. 12.1.4.1 Company overview 12.1.4.2 Product benchmarking 12.1.4.3 Strategic initiatives 12.1.5 Peptron, Inc 12.1.5.1 Company overview 12.1.5.2 Financial Performance 12.1.5.3 Product benchmarking 12.1.5.4 Strategic initiatives 12.1.6 WOCKHARDT 12.1.6.1 Company overview 12.1.6.2 Financial performance 12.1.6.3 Product benchmarking 12.1.6.4 Strategic initiatives 12.1.7 Dauntless Pharmaceuticals 12.1.7.1 Company overview 12.1.7.2 Product benchmarking 12.1.7.3 Strategic initiatives 12.1.8 Pfizer Inc. Follow Us:

  8. 12.1.8.1 Company overview 12.1.8.2 Financial performance 12.1.8.3 Product benchmarking 12.1.8.4 Strategic initiatives 12.1.9 Ionis Pharmaceuticals, Inc. 12.1.9.1 Company overview 12.1.9.2 Product benchmarking 12.1.9.3 Strategic initiatives Chapter 13 Recommendations/Conclusion 13.1 Recommendations 13.2 Conclusion About Grand View Research, Inc.: Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy. Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc Phone: 1-415- 349-0058 Toll Free: 1-888- 202-9519 Email:sales@grandviewresearch.com For More Information:https://www.grandviewresearch.com Follow Us:

More Related